Product logins

Find logins to all Clarivate products below.


Breast Cancer – Epidemiology – Epidemiology Dashboard

Clarivate Epidemiology’s coverage of breast cancer comprises epidemiological estimates of key patient populations in 45 countries worldwide. We report both the diagnosed incidence and diagnosed prevalence of breast cancer for each country, as well as annualized case counts projected to the national population.

Most patient populations are forecast over a period of 20 years for the mature markets and Europe, and 10 years for the other countries we cover.

All forecast data are available on Clarivate Insights Platform in tabular format, with options to download to MS Excel. All populations are accompanied by a comprehensive description of the methods and data sources used, with hyperlinks to external sources. A summary evidence table generated as part of our systematic review of the epidemiological literature is also provided for full transparency into research and methods. In addition, we provide a graph depicting the patient flow between or within different disease states for the major mature pharmaceutical markets. These patient-flow diagrams are provided at the regional level but may be requested for any specific country or forecast year.

Clarivate Epidemiology’s breast cancer forecast answers the following questions:

  • In developing countries, what impact will economic growth and development have on the number of people diagnosed with breast cancer each year?
  • Of all people diagnosed with breast cancer, how many in each of the major mature pharmaceutical markets are drug-treated?
  • How will demographic trends, such as population aging and improving life expectancy, affect the epidemiology of breast cancer over the forecast period?

In addition to the total number of cases for each forecast year, Clarivate Epidemiology provides at least 10 years of forecast data for the following breast cancer populations:

  • Breast cancer by stage at diagnosis
  • Metastatic recurrent incident cases
  • Drug-treatable populations
  • Drug-treated populations

Note: Coverage may vary by country.

Related Market Assessment Reports

Report
Breast Cancer – Geographic Focus: China – China In-Depth – Breast Cancer
China’s breast cancer market continues to evolve rapidly, driven by rising incidence and expanding systemic treatment options. Several new and emerging therapies are expected to gain approval for…
Report
Squamous Cell Carcinoma of the Head and Neck – Geographic Focus: China – China In-Depth – Squamous Cell Carcinoma of the Head and Neck
China’s SCCHN market is undergoing rapid transformation, driven by the expanding use of systemic therapies beyond traditional surgery and radiotherapy. Current treatment options include…
Report
Bladder Cancer and Upper Tract Urothelial Carcinoma – Geographic Focus: China – Bladder Cancer and Upper Tract Urothelial Carcinoma – China In-Depth – China
China’s bladder cancer market is entering a period of accelerated expansion, as novel branded therapies reshape systemic management. A major growth driver is the expanding role of immune…
Report
Biomarkers in Oncology – Access & Reimbursement – Access & Reimbursement – Biomarkers in Oncology – Biomarker-Driven Prescribing in NSCLC, Colorectal Cancer, Breast Cancer (US)
The increasing focus on biomarkers has reshaped the treatment paradigm in oncology, allowing physicians to tailor treatments to subpopulations of patients diagnosed with breast cancer, NSCLC and…
Report
Endometrial Carcinoma – Landscape & Forecast – Disease Landscape & Forecast (G7)
The treatment landscape for endometrial carcinoma is undergoing rapid transformation, fueled by the increasing use of immune checkpoint inhibitors and advances in molecular classification. In the…